SAB Biotherapeutics, Inc. (SABS)

NASDAQ: SABS · USD

$3.19

+0.12 (+3.9%)· Recorded snapshot

Market cap	290.2M
Net income (ttm)	-21.8M
EPS (ttm)	-$1.56
Shares out	91M
Volume	300,016
Beta	0.58

Market data

Price

Recent price action with selectable time range.

Financial snapshot

Net income (ttm): -21.8M
EPS (ttm): -$1.56
Market cap: 290.2M

Ticker	Name	Market cap	P/E	P/S	ROIC	5Y rev CAGR	1Y total return	Rating
EXAS	Exact Sciences Corp	—	—	—	—	—	—	Aanhouden

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector percentile context

Refreshed 2026-10-28 19:55 UTC

Forward P/En/a

P25 13.4P50 20.2P75 35.7

Trailing P/En/a

P25 15.4P50 25.8P75 43.5

ROE-11.3

P25 -113.8P50 -46.5P75 -0.9

ROIC-37.7

P25 -68.5P50 -27.1P75 1.8

Benchmarks · 1M

All SABS indicators

Market & fundamental data

Available fields

182

Groups with data

Currency

USD

Showing 182 of 182 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Amount currency	USD
CIK code	0001833214
Company name	SAB Biotherapeutics, Inc.
Country	United States
Country code	US
CUSIP number	78397T202
Earnings date	2026-11-12
Earnings time	amc
Employees	86
Employees change	23
Employees growth	36.51%
Enterprise value	$192.7M
Exchange	NASDAQ
Financial currency	USD
Financial report date	2026-06-30
First seen	2026-05-09
Fiscal year end	December
Founded	2014
In index	RUSSELL2000
Industry	Biotechnology
Is primary listing	Yes
Is SPAC	No
ISIN number	US78397T2024
Last 10-K release date	2026-03-09
Last earnings date	2026-08-06
Last refreshed	2026-10-28
Last stock split date	2024-01-05
Last stock split type	Reverse
Market cap	$290.2M
Market cap category	Micro-Cap
Next earnings date	2026-11-12
Options	Yes
Price	$3.19
Price currency	USD
Sector	Healthcare
SIC code	2836
Stock price date	2026-10-28
Symbol	SABS
U.S. state	Florida
Website	https://www.sab.bio

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings yield	-48.78%
FCF / EV yield	-30.23%
FCF yield	-19.98%
P/B ratio	1.19x
Price / tangible book value	1.34x
Sector forward P/E	23.53x
Sector P/E	51.01x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
Profit per employee	$-253,346
Profitable years	1
ROA	-33.46%
ROA (5Y)	-28.98%
ROCE	-31.71%
ROE	-11.27%
ROE (5Y)	-52.1%
ROIC	-37.67%

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
EPS growth quarters	4
EPS growth years	2
Net income growth years	2
Revenue growth years	0

Financial statements

Income-statement and cash-flow amounts, totals and per share.

Metric	Value
Capital expenditures	$-3.5M
Depreciation and amortization	$3.1M
EBIT	$-71.8M
EBITDA	$-68.7M
EPS	$-1.56
FCF per share	$-0.63
Financing cash flow	$260.9M
Free cash flow	$-57.4M
Free cash flow minus SBC	$-74.1M
Gross profit	$-48.3M
Investing cash flow	$-202.1M
Net borrowing	$-148,412
Net cash flow	$4.6M
Net income	$-21.8M
Operating cash flow minus SBC	$-70.6M
Operating income	$-71.8M
Stock-based compensation	$16.7M

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Book value per share	$2.57
Debt / equity	0.02
Interest coverage	-310.04
Long-term assets	$130.3M
Long-term liabilities	$11.7M
Net cash (debt)	$97.5M
Net cash / market cap	33.91%
Net debt / equity	-0.45
Piotroski F-Score	1
Property, plant and equipment	$19.6M
Shareholders' equity	$214.8M
Tangible book value	$214.8M
Tangible book value per share	$2.57
Total assets	$238.2M
Total cash	$102.6M
Total debt	$5.1M
Total liabilities	$23.4M
WACC	7.39%

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current assets	$107.9M
Current liabilities	$11.7M
Current ratio	9.22
Net working capital	$-5.8M
Quick ratio	8.93
Working capital	$96.2M

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback yield / dilution	-417.54%
Dividend yield	0%
Shareholder yield	-417.54%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
150-day SMA	$3.57
1D price change	3.91%
1M price change	-3.19%
1M total return	-3.19%
1W price change	10.59%
1W total return	10.59%
1Y price change	5.12%
1Y return CAGR	5.12%
1Y total return	5.12%
20-day SMA	$2.86
200-day SMA	$3.69
3M price change	-7.41%
3M total return	-7.41%
3Y price change	-67.5%
3Y return CAGR	-31.24%
3Y total return	-67.5%
50-day SMA	$3.28
50-day SMA vs 200-day SMA	50under200
52-week high	$5.15
52-week high date	2026-03-12
52-week low	$2.44
52-week low date	2026-10-19
5Y price change	-96.04%
5Y return CAGR	-47.59%
5Y total return	-96.04%
6M price change	-8.21%
6M total return	-8.21%
All-time high	$129.00
All-time high date	2021-10-22
All-time low	$1.00
All-time low date	2025-04-04
Average true range (ATR)	$0.21
Average volume	661K
Beta (1Y)	0.85
Beta (2Y)	1.02
Beta (5Y)	0.58
Change from 52-week high	-38.06%
Change from 52-week low	30.74%
Change from all-time high	-97.53%
Change from all-time low	218.5%
Change from open	1.59%
Day's gap	2.28%
Dollar volume	$957,051
High price	$3.20
Low price	$3.12
Monthly RSI	36.78
Open price	$3.14
Position in 52-week range	88.24%
Premarket change	0%
Premarket close	$3.07
Premarket price	$3.07
Premarket volume	899
Previous close	$3.07
Price vs 150-day SMA	-10.86%
Price vs 20-day SMA	11.44%
Price vs 200-day SMA	-13.62%
Price vs 50-day SMA	-2.78%
Relative volume	0.45
RSI	55.79
Sharpe ratio	0.32
Sharpe ratio (3Y)	0.05
Sharpe ratio (5Y)	-0.11
Sortino ratio	0.6
Sortino ratio (3Y)	0.14
Sortino ratio (5Y)	-0.13
Volume	300K
Weekly RSI	46.41
YTD price change	-14.84%
YTD total return	-14.84%

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	62M
Float percentage	68.19%
Shares change (QoQ)	48.91%
Shares change (YoY)	417.54%
Shares held by insiders	0.65%
Shares held by institutions	45.12%
Shares outstanding	91M
Short % of float	6.92%
Short % of shares	4.72%
Short ratio	7.6 days

Deeper analysis on SABS

14 sections in the full report · jump straight to what you need

Forecast

Base and Bull forecast paths with report-date return framing.

→

Valuation

Fair-value bridge, DCF, owner earnings, and peer multiples.

→

Sensitivity

Cost-of-equity and terminal-growth stress table.

→

Risks

Kill scenarios, soft-pass flags, and downside catalysts.

→

Earnings

Next earnings setup and beat / inline / miss thresholds.

→

Position sizing

Entry, exit, conviction, and quarterly monitoring rules.

→

Financials

Revenue, margins, cash flow, and balance-sheet context.

→

Peers

Relative valuation and profitability against the cohort.

→

Moat

Economic-profit evidence and competitive advantage risk.

→

Industry cycle

Sector phase, capital cycle, and secular tailwinds.

→

Frequently asked questions

About this SABS report

Is a complete SABS research report available?

No complete published report is available for SAB Biotherapeutics, Inc. (SABS) on this page. Market-directory data, when present, is not a substitute for a validated stock analysis.

SAB Biotherapeutics, Inc. (SABS)

Price

Financial snapshot

Fair-value bridge

Latest news · SABS

Valuation

Profitability

Balance sheet

Trading

Next earnings

Sector percentile context

All SABS indicators

Profile and market data

Valuation

Profitability

Growth

Financial statements

Financial strength

Liquidity

Dividends and buybacks

Performance and technicals

Ownership and float

Deeper analysis on SABS

Frequently asked questions